|DB00209||Trospium||For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.|
|DB00346||Alfuzosin||For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.|
|DB00496||Darifenacin||For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.|
|DB00551||Acetohydroxamic acid||Used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.|
|DB00686||Pentosan Polysulfate||For the relief of bladder pain or discomfort associated with interstitial cystitis.|
|DB00706||Tamsulosin||Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.[Label]
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.[A178339,L6259]|
|DB00770||Alprostadil||For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.|
|DB00820||Tadalafil||Used for the treatment of erectile dysfunction.|
|DB00862||Vardenafil||Used for the treatment of erectile dysfunction|
|DB01036||Tolterodine||For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).|
|DB01062||Oxybutynin||For the treatment of overactive bladder.|
|DB01126||Dutasteride||Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with [tamsulosin].[label]|
|DB01148||Flavoxate||For symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.|
|DB01162||Terazosin||Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label].|
|DB01164||Calcium Chloride||For the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels, for the treatment of magnesium intoxication due to overdosage of magnesium sulfate, and used to combat the deleterious effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the increased potassium level in the extracellular fluid.|
|DB01216||Finasteride||Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.
Indicated for the treatment of male pattern hair loss (androgenetic alopecia, hereditary alopecia, or common male baldness) in male patients. |
|DB01392||Yohimbine||Indicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.|
|DB01438||Phenazopyridine||For the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.|
|DB01591||Solifenacin||For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.|
|DB04884||Dapoxetine||For the treatment of premature ejaculation.|
|DB06207||Silodosin||Treatment for symptomatic relief of benign prostatic hyperplasia |
|DB06237||Avanafil||Treatment of erectile dysfunction in males. |
|DB06267||Udenafil||Investigated for use/treatment in erectile dysfunction and hypertension.|
|DB06702||Fesoterodine||For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).|
|DB08893||Mirabegron||Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.|
|DB09104||Magnesium hydroxide||Magnesium hydroxide can be used as an antacid or a laxative depending on the administered dose.
As an antacid, it is used for the temporary relief of heartburn, upset stomach, sour stomach or acid indigestion.
As a laxative, it is used for the relief of occasional constipation by promoting bowel movements for 30 minutes and up to 6 hours.
|DB09205||Moxisylyte||By the WHO, moxisylyte is indicated for the symptomatic management of sequelae of cerebral infarction or hemorrhage.[T91] The cerebral infarction is characterized by the blockage of the artery either by the formation of a thrombus or an embolus.[A31644]
On the other hand, the FDA classified moxisylyte for the reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma.[L1172] Closed-angle glaucoma is caused by the contact between the iris and the trabecular meshwork. This contact will damage the aqueous outflow by the meshwork thus, increasing eye pressure and producing the symptoms of glaucoma.[A31645] Mydriasis is referred to the dilatation of the pupils and this standard body function is known to be a trigger factor for the development of acute closed-angle glaucoma.This risk is explained by the generation of a pupillary block, which is the contact between the pupillary margins and the lens, thus preventing flow from the aqueous humor to the anterior chamber and followed by an increased pressure gradient.[L1173]
Moxisylyte is also approved in France as the first drug for the treatment of impotence.[A31647]|
|DB11071||Phenyl salicylate||Pain and fever [L2468].|
|DB12278||Propiverine||Indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB) [L2315]. Propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury [A32581].|
|DB00714||Apomorphine||For the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson's disease.|
|DB01093||Dimethyl sulfoxide||For the symptomatic relief of patients with interstitial cystitis.|
|DB01113||Papaverine||For the treatment of impotence and vasospasms.|
|DB06767||Ammonium chloride||1. Expectorant in cough syrups.
2. The ammonium ion (NH4+) in the body plays an important role in the maintenance of acid-base balance. The kidney uses ammonium (NH4+) in place of sodium (Na+) to combine with fixed anions in maintaining acid-base balance, especially as a homeostatic compensatory mechanism in metabolic acidosis.
The therapeutic effects of Ammonium Chloride depend upon the ability of the kidney to utilize ammonia in the excretion of an excess of fixed anions and the conversion of ammonia to urea by the liver, thereby liberating hydrogen (H+) and chloride (Cl–) ions into the extracellular fluid.
Ammonium Chloride Injection, USP, after dilution in isotonic sodium chloride injection, may be indicated in the treatment of patients with:
(1) hypochloremic states and (2) metabolic alkalosis.|
|DB06823||Tiopronin||Tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mg/day, and who have failed treatment with non-pharmacological measures of increased fluid intake, decreased sodium and protein intake, and urine alkalinization.|
|DB00203||Sildenafil||Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:
(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and
(2) treatment of pulmonary hypertension, where:
a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];
b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and
c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].|